Mass Tort brief
Federal Formula Wins and High Court Class Actions
Federal bellwether victories, High Court claimant disputes, and growing product liability reserves shape major UK corporate litigation risks.
Mass Tort
Reckitt Benckiser won the first federal NEC formula bellwether trial — eliminating immediate legal liabilities and lifting its market cap by £1bn.
BackgroundThousands of parents sued infant formula manufacturers alleging cow's-milk formulas caused necrotizing enterocolitis in premature infants. Reckitt Benckiser faced multi-billion-pound legal liabilities that severely depressed its LSE equity valuation over the past year.
- The jury rejected claims that Enfamil formula caused NEC or lacked adequate warning labels for hospital neonatologists.
- The defense verdict leaves zero active adverse federal trial judgments against Mead Johnson across US multidistrict litigation.
- Reckitt executive leadership confirmed plans to proceed with divesting the Mead Johnson nutrition business following the legal win.
Mass Tort
Rival law firms are fighting for control of 420,000 claimants in London's High Court — delaying multi-billion-pound payouts for BHP's dam disaster.
BackgroundThe 2015 Fundão dam collapse in Brazil released toxic mining waste, destroying entire communities in the country's worst environmental disaster. Pogust Goodhead organized 420,000 Brazilian victims to sue Anglo-Australian miner BHP in London in the largest class-style action in UK legal history.
- Rival law firm Bailey Glasser filed court claims seeking lead solicitor status for the 420,000 English group litigation claimants.
- The High Court ruled BHP strictly liable, setting up Phase 2 trials to determine multi-billion-pound compensation payouts.
- The legal representation clash highlights the immense financial stakes behind managing historical High Court mass tort actions.
Mass Tort
Indivior faces 1,800 Suboxone dental injury lawsuits — hitting operating cash flows as legal reserves grow.
BackgroundSlough-headquartered Indivior produces Suboxone to treat opioid use disorder, generating significant revenues across US healthcare markets. Plaintiffs accuse Indivior of failing to warn doctors about acidic sublingual film risks before updating warning labels in 2022.
- Over 1,800 active personal injury claims are consolidated in federal multidistrict litigation in Ohio.
- Indivior's quarterly filings show operating cash flows hit by ongoing litigation defense reserves and settlement holdbacks.
- Judicial orders established an 11% holdback fund on future settlements to cover common-benefit leadership legal fees.
Mass Tort
A $40 million jury verdict against Bard's defective catheter sets a high settlement benchmark across 4,000 pending MDL claims.
BackgroundBard PowerPort devices are implanted under the skin to deliver long-term chemotherapy treatments directly into bloodstream channels. Plaintiffs allege the catheters suffer design defects that cause internal fracturing, leading to catastrophic vascular tears and emergency cardiac surgeries.
- The jury found C.R. Bard liable for negligent design defects and failure to adequately warn medical professionals.
- Over 4,000 product liability claims are pending in federal multidistrict litigation targeting Becton Dickinson.
- Additional bellwether trials scheduled for late 2026 will establish settlement valuation benchmarks across NHS and global healthcare supply chains.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
